{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:56:32Z","timestamp":1760100992657,"version":"build-2065373602"},"reference-count":90,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology Nursing"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.soncn.2017.05.003","type":"journal-article","created":{"date-parts":[[2017,7,3]],"date-time":"2017-07-03T09:31:51Z","timestamp":1499074311000},"page":"254-264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Strategies for Selecting the Optimal Treatment in Newly Diagnosed Multiple Myeloma Patients"],"prefix":"10.1016","volume":"33","author":[{"given":"Mary","family":"Steinbach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany","family":"Richards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth","family":"Faiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.soncn.2017.05.003_bib0010","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.soncn.2017.05.003_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.soncn.2017.05.005","article-title":"Immunomodulatory drugs and protease inhibitors in the treatment of multiple myeloma","volume":"33","author":"Noonan","year":"2017","journal-title":"Semin Oncol Nurs"},{"issue":"3","key":"10.1016\/j.soncn.2017.05.003_bib0020","article-title":"Immunotherapy in multiple myeloma","volume":"33","author":"Catamero","year":"2017","journal-title":"Semin Oncol Nurs"},{"key":"10.1016\/j.soncn.2017.05.003_bib0025","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/ajh.2830330203","article-title":"VAD-based regimens as primary treatment for multiple myeloma","volume":"33","author":"Alexanian","year":"1990","journal-title":"Am J Hematol"},{"key":"10.1016\/j.soncn.2017.05.003_bib0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-540-85772-3_1","article-title":"History of multiple myeloma","volume":"183","author":"Kyle","year":"2011","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.soncn.2017.05.003_bib0035","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1200\/JCO.1998.16.12.3832","article-title":"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials","volume":"16","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.soncn.2017.05.003_bib0040","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1200\/JCO.1992.10.2.334","article-title":"Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials","volume":"10","author":"Gregory","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.soncn.2017.05.003_bib0045","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3816\/CLM.2001.n.008","article-title":"Management of patients with multiple myeloma: emphasizing the role of high-dose therapy","volume":"2","author":"Kyle","year":"2001","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.soncn.2017.05.003_bib0050","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/sj.thj.6200312","article-title":"Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation","volume":"4","author":"Durie","year":"2003","journal-title":"Hematol J"},{"key":"10.1016\/j.soncn.2017.05.003_bib0055","first-page":"7","article-title":"Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group","volume":"95","author":"Lenhoff","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.soncn.2017.05.003_bib0060","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1001\/archderm.1984.01650390060012","article-title":"Thalidomide neurotoxicity","volume":"120","author":"Clemmensen","year":"1984","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.soncn.2017.05.003_bib0065","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soncn.2017.05.003_bib0070","doi-asserted-by":"crossref","first-page":"897","DOI":"10.4065\/75.9.897","article-title":"Thalidomide in the treatment of relapsed multiple myeloma","volume":"75","author":"Rajkumar","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.soncn.2017.05.003_bib0075","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soncn.2017.05.003_bib0080","first-page":"191","article-title":"Targeting proteasome inhibition in hematologic malignancies","volume":"7","author":"Hideshima","year":"2003","journal-title":"Rev Clin Exp Hematol"},{"key":"10.1016\/j.soncn.2017.05.003_bib0085","first-page":"6316","article-title":"The proteasome as a target for cancer therapy","volume":"9","author":"Voorhees","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.soncn.2017.05.003_bib0090","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.soncn.2017.05.003_bib0095","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/leu.2011.346","article-title":"Management of treatment-emergent peripheral neuropathy in multiple myeloma","volume":"26","author":"Richardson","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.soncn.2017.05.003_bib0100","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.soncn.2017.05.003_bib0105","article-title":"Results of PX-171-003-A1, an open-label, single-arm, phase 2 (Ph 2) study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM)","volume":"116","author":"Siegel","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.soncn.2017.05.003_bib0110","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.mvr.2005.01.002","article-title":"Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro","volume":"69","author":"Dredge","year":"2005","journal-title":"Microvasc Res"},{"key":"10.1016\/j.soncn.2017.05.003_bib0115","doi-asserted-by":"crossref","first-page":"11712","DOI":"10.1158\/0008-5472.CAN-05-1657","article-title":"Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40\u2013induced cytotoxicity in human multiple myeloma: clinical implications","volume":"65","author":"Tai","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.soncn.2017.05.003_bib0120","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdl313","article-title":"Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy","volume":"17","author":"Baz","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.soncn.2017.05.003_bib0125","volume":"120","author":"Richardson","year":"2012","journal-title":"Blood"},{"author":"Novartis","key":"10.1016\/j.soncn.2017.05.003_bib0130"},{"year":"2015","series-title":"Ninlaro\u00ae (ixazomib) Prescribing Information","author":"Takeda Oncology","key":"10.1016\/j.soncn.2017.05.003_bib0135"},{"year":"2017","series-title":"EMPLICITI\u00ae (Elotuzumab) [Package Insert]","author":"Bristol-Myers Squibb Company","key":"10.1016\/j.soncn.2017.05.003_bib0140"},{"year":"2015","series-title":"DARZALEX\u00ae (Daratumumab). Package insert","author":"Janssen","key":"10.1016\/j.soncn.2017.05.003_bib0145"},{"issue":"3","key":"10.1016\/j.soncn.2017.05.003_bib0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.soncn.2017.05.012","article-title":"Pathobiology and diagnosis of multiple myeloma","volume":"33","author":"Brigle","year":"2017","journal-title":"Semin Oncol Nurs"},{"key":"10.1016\/j.soncn.2017.05.003_bib0155","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.soncn.2017.05.003_bib0160","first-page":"272","article-title":"Evolving diagnostic criteria for multiple myeloma","volume":"2015","author":"Rajkumar","year":"2015","journal-title":"ASH Educ Program Book"},{"key":"10.1016\/j.soncn.2017.05.003_bib0170","first-page":"17","article-title":"Sequencing and integration of clinical trials","volume":"7","author":"Faiman","year":"2016","journal-title":"J Adv Pract Oncol"},{"key":"10.1016\/j.soncn.2017.05.003_bib0175","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1634\/theoncologist.2015-0481","article-title":"Financial burden of cancer clinical trial participation and the impact of a cancer care equity program","volume":"21","author":"Nipp","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.soncn.2017.05.003_bib0180","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2015.63.2257","article-title":"Randomized trial of a web-based intervention to address barriers to clinical trials","volume":"34","author":"Meropol","year":"2016","journal-title":"J Clin Oncol"},{"year":"2017","series-title":"NCCN Multiple Myeloma Clinical Practice Guidelines in Oncology v2.2017. The Complete Library of NCCN Clinical Practice Guidelines in Oncology","author":"The National Comprehensive Cancer Network","key":"10.1016\/j.soncn.2017.05.003_bib0185"},{"key":"10.1016\/j.soncn.2017.05.003_bib0190","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.781.781","article-title":"Bortezomib-based induction treatments improve outcomes of newly diagnosed multiple myeloma patients with high-risk cytogenetic abnormalities","volume":"116","author":"Cavo","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.soncn.2017.05.003_bib0195","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.3324\/haematol.2012.081083","article-title":"Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma","volume":"98","author":"Van Wier","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.soncn.2017.05.003_bib0200","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/leu.2013.335","article-title":"Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients","volume":"28","author":"Nooka","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.soncn.2017.05.003_bib0205","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.2106.2106","article-title":"Connect MM\u00ae \u2013 the Multiple Myeloma (MM) Disease Registry: interim analysis of overall survival and outcomes in patients with high-risk disease","volume":"124","author":"Shah","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.soncn.2017.05.003_bib0210","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.soncn.2017.05.003_bib0215","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.25.25","volume":"126","author":"Durie","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.soncn.2017.05.003_bib0220","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.blre.2015.06.001","article-title":"Treatment for patients with newly diagnosed multiple myeloma in 2015","volume":"29","author":"Mateos","year":"2015","journal-title":"Blood Rev"},{"key":"10.1016\/j.soncn.2017.05.003_bib0225","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/leu.2013.185","article-title":"Review of health-related quality of life data in multiple myeloma patients treated with novel agents","volume":"27","author":"Sonneveld","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.soncn.2017.05.003_bib0230","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma: an International Myeloma Working Group report","volume":"126","author":"Palumbo","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.soncn.2017.05.003_bib0235","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.soncn.2017.05.003_bib0240","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3324\/haematol.2016.148189","article-title":"Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores","volume":"101","author":"Engelhardt","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.soncn.2017.05.003_bib0245","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1200\/JCO.2014.60.2466","article-title":"Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.soncn.2017.05.003_bib0250","doi-asserted-by":"crossref","first-page":"E70","DOI":"10.1188\/12.ONF.E70-E83","article-title":"Physician, patient, and contextual factors affecting treatment decisions in older adults with cancer and models of decision making: a literature review","volume":"39","author":"Tariman","year":"2012","journal-title":"Oncol Nurs Forum"},{"key":"10.1016\/j.soncn.2017.05.003_bib0255","first-page":"34","article-title":"Patient, physician and contextual factors are influential in the treatment decision making of older adults newly diagnosed with symptomatic myeloma","volume":"2","author":"Tariman","year":"2014","journal-title":"Cancer Treat Commun"},{"key":"10.1016\/j.soncn.2017.05.003_bib0260","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1188\/15.CJON.548-556","article-title":"The evolving role of the nurse during the cancer treatment decision-making process: a literature review","volume":"19","author":"Tariman","year":"2015","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.soncn.2017.05.003_bib0265","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1188\/16.CJON.560-563","article-title":"Oncology nursing and shared decision making for cancer treatment","volume":"20","author":"Tariman","year":"2016","journal-title":"Clin J Oncol Nurs"},{"author":"Newport","key":"10.1016\/j.soncn.2017.05.003_bib0270"},{"author":"Riffkin","key":"10.1016\/j.soncn.2017.05.003_bib0275"},{"key":"10.1016\/j.soncn.2017.05.003_bib0280","first-page":"377","article-title":"Implementing and evaluating shared decision making in oncology practice","volume":"64","author":"Kane","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.soncn.2017.05.003_bib0285","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.4065\/83.10.1142","article-title":"Treatment of myeloma: cure vs control","volume":"83","author":"Rajkumar","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.soncn.2017.05.003_bib0290","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0025-6196(11)61029-X","article-title":"Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): consensus statement","volume":"82","author":"Dispenzieri","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.soncn.2017.05.003_bib0295","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.2620.2620","article-title":"Results of an upfront myeloma carepath pilot with response-adapted therapy","volume":"124","author":"Narkhede","year":"2014","journal-title":"Blood"},{"issue":"suppl","key":"10.1016\/j.soncn.2017.05.003_bib0300","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1188\/13.CJON.S2.33-41","article-title":"Clinical updates in blood and marrow transplantation in multiple myeloma","volume":"17","author":"Faiman","year":"2013","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.soncn.2017.05.003_bib0305","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1038\/leu.2011.131","article-title":"Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy","volume":"25","author":"Cavallo","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.soncn.2017.05.003_bib0310","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soncn.2017.05.003_bib0315","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1182\/blood-2014-11-568907","article-title":"New criteria for response assessment: role of minimal residual disease in multiple myeloma","volume":"125","author":"Paiva","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.soncn.2017.05.003_bib0320","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood-2010-09-307645","article-title":"Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients","volume":"117","author":"Gay","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.soncn.2017.05.003_bib0325","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/ejh.12829","article-title":"Association between complete response and outcomes in transplant-eligible myeloma patients in the era of novel agents","volume":"98","author":"van de Velde","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.soncn.2017.05.003_bib0330","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis","volume":"119","author":"Mikhael","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.soncn.2017.05.003_bib0335","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","volume":"11","author":"Mateos","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.soncn.2017.05.003_bib0340","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.1968.1968","article-title":"Higher cumulative bortezomib dose results in better overall survival (OS) in patients with previously untreated multiple myeloma (MM) receiving bortezomib-melphalan-prednisone (VMP) in the phase 3 VISTA study","volume":"122","author":"Mateos","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.soncn.2017.05.003_bib0345","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1586\/17474086.2014.864230","article-title":"Initial treatment of transplant-ineligible patients in multiple myeloma","volume":"7","author":"Mateos","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.soncn.2017.05.003_bib0350","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.3457.3457","article-title":"Persistent benefit of VTD (bortezomib\/thalidomide\/dexamethasone) as pretransplant induction therapy for multiple myeloma: long-term follow-up of a randomized phase 3 Pethema\/GEM study","volume":"124","author":"Rosi\u00f1ol","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.soncn.2017.05.003_bib0355","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/j.bbmt.2015.09.016","volume":"21","author":"Giralt","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.soncn.2017.05.003_bib0360","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.391.391","article-title":"Autologous transplantation for multiple myeloma in the era of new drugs: a phase III study of the Intergroupe Francophone du Myelome (IFM\/DFCI 2009 Trial)","volume":"126","author":"Attal","year":"2015","journal-title":"Blood"},{"issue":"suppl","key":"10.1016\/j.soncn.2017.05.003_bib0365","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1188\/13.CJON.S2.13-24","article-title":"Autologous hematopoietic stem cell transplantation for patients with multiple myeloma: an overview for nurses in community practice","volume":"17","author":"Miceli","year":"2013","journal-title":"Clin J Oncol Nurs"},{"issue":"3","key":"10.1016\/j.soncn.2017.05.003_bib0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.soncn.2017.05.004","article-title":"Hematopoietic stem cell transplantation for multiple myeloma","volume":"33","author":"Koniarczyk","year":"2017","journal-title":"Semin Oncol Nurs"},{"key":"10.1016\/j.soncn.2017.05.003_bib0375","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1182\/blood-2011-11-374249","article-title":"IMWG consensus on maintenance therapy in multiple myeloma","volume":"119","author":"Ludwig","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.soncn.2017.05.003_bib0380","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soncn.2017.05.003_bib0385","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soncn.2017.05.003_bib0390","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.37.37","article-title":"Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma: CALGB 100104","volume":"116","author":"McCarthy","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.soncn.2017.05.003_bib0395","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1182\/blood.V128.22.1143.1143","article-title":"Lenalidomide is a highly effective maintenance therapy in myeloma patients of all ages; results of the phase III myeloma XI study","volume":"128","author":"Jackson","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.soncn.2017.05.003_bib0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.soncn.2017.05.008","article-title":"evidence-based guidelines for preventing and managing side effects of multiple myeloma","volume":"33","author":"Bertolotti","year":"2017","journal-title":"Semin Oncol Nurs"},{"issue":"suppl","key":"10.1016\/j.soncn.2017.05.003_bib0405","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1188\/08.CJON.S1.13-19","article-title":"Myelosuppression associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board","volume":"12","author":"Miceli","year":"2008","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.soncn.2017.05.003_bib0410","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1200\/JCO.2007.14.9641","article-title":"Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study","volume":"26","author":"Chanan-Khan","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3 suppl","key":"10.1016\/j.soncn.2017.05.003_bib0415","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1188\/08.CJON.S1.21-27","article-title":"Thromboembolic events associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board","volume":"12","author":"Rome","year":"2008","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.soncn.2017.05.003_bib0420","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide-and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.soncn.2017.05.003_bib0425","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1188\/11.S1.CJON.9-23","article-title":"Maintaining bone health in patients with multiple myeloma: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board","volume":"15","author":"Miceli","year":"2011","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.soncn.2017.05.003_bib0430","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1188\/17.CJON.240-249","article-title":"Steroid-associated side effects: a symptom management update on multiple myeloma treatment","volume":"21","author":"King","year":"2017","journal-title":"Clin J Oncol Nurs"},{"issue":"suppl","key":"10.1016\/j.soncn.2017.05.003_bib0435","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1188\/11.CJON.S1.66-76","article-title":"Renal complications in multiple myeloma and related disorders: survivorship care plan of the IMF Nurse Leadership Board","volume":"15","author":"Faiman","year":"2011","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.soncn.2017.05.003_bib0440","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soncn.2017.05.003_bib0445","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"issue":"suppl","key":"10.1016\/j.soncn.2017.05.003_bib0450","article-title":"Carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed multiple myeloma (RMM): results from the phase III study ENDEAVOR. American Society of Clinical Oncology","volume":"33","author":"Dimopoulos","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.soncn.2017.05.003_bib0455","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","article-title":"International Myeloma Working Group recommendations for the treatment of multiple myeloma\u2013related bone disease","volume":"31","author":"Terpos","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3 suppl","key":"10.1016\/j.soncn.2017.05.003_bib0460","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1188\/08.CJON.S1.9-12","article-title":"Management of side effects of novel therapies for multiple myeloma: consensus statements developed by the International Myeloma Foundation's Nurse Leadership Board","volume":"12","author":"Bertolotti","year":"2008","journal-title":"Clin J Oncol Nurs"}],"container-title":["Seminars in Oncology Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208117300384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208117300384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T07:31:48Z","timestamp":1760081508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749208117300384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":90,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0749208117300384"],"URL":"https:\/\/doi.org\/10.1016\/j.soncn.2017.05.003","relation":{},"ISSN":["0749-2081"],"issn-type":[{"type":"print","value":"0749-2081"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strategies for Selecting the Optimal Treatment in Newly Diagnosed Multiple Myeloma Patients","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology Nursing","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soncn.2017.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}